Skip to main content

Table 2 Sociodemographic and clinical characteristics of patients that participated in the various components (PROMs, interview, biobank) and subcomponents (accelerometer, tumour biopsy, blood, oral rinse and saliva) of NET-QUBIC at baseline

From: Study retention and attrition in a longitudinal cohort study including patient-reported outcomes, fieldwork and biobank samples: results of the Netherlands quality of life and Biomedical cohort study (NET-QUBIC) among 739 head and neck cancer patients and 262 informal caregivers

 

PROMsa

Yes

N = 605

PROMsa

No

N = 134

P-value

Fieldwork

Yes

N = 578

Fieldwork

No

N = 161

P-value

Biobank

Yes

N = 718

Biobank

No

N = 21

P-value

Gender, n (%)

 Men

450 (74%)

99 (74%)

0.90

438 (76%)

111 (69%)

0.08

536 (75%)

13 (62%)

0.19

 Women

155 (26%)

35 (26%)

 

140 (24%)

50 (31%)

 

182 (25%)

8 (38%)

 

Age, mean ± SD years

63.5 ± 9.5

62.0 ± 10.9

0.14

63.6 ± 9.3

61.9 ± 11.0

0.06

63 ± 9.7

62 ± 11.3

0.57

Tumor location, n (%)

  

0.29

  

0.33

  

0.47c

 Oral Cavity

168 (28%)

31 (23%)

 

147 (25%)

52 (32%)

 

191 (27%)

8 (38%)

 

 Oropharynx

211 (35%)

51 (38%)

 

212 (37%)

50 (31%)

 

256 (36%)

6 (29%)

 

 Hypopharynx

38 (6%)

14 (10%)

 

38 (7%)

14 (9%)

 

52 (7%)

0 (0%)

 

 Larynx

169 (28%)

36 27%)

 

164 (28%)

41 (25%)

 

199 (28%)

6 (29%)

 

 Unknown primary

19 (3%)

2 (1%)

 

17 (3%)

4 (2%)

 

20 (3%)

1 (5%)

 

Clinical disease Stage, n (%)

  

0.011

  

0.16

  

0.87c

 0/I

147 (24%)

16 (12%)

 

133 (23%)

30 (19%)

 

159 (22%)

4 (19%)

 

 II

108 (18%)

24 (18%)

 

94 (16%)

38 (24%)

 

129 (18%)

3 (14%)

 

 III

97 (16%)

30 (22%)

 

99 (17%)

28 (17%)

 

122 (17%)

5 (24%)

 

 IV

253 (42%)

64 (48%)

 

252 (44%)

65 (40%)

 

308 (43%)

9 (43%)

 

Treatment, n (%)b

  

0.46

  

0.75

  

0.16

 Single treatment

326 (54%)

67 (50%)

 

306 (53%)

87 (54%)

 

385 (54%)

8 (38%)

 

 Combination treatment

279 (46%)

66 (50%)

 

272 (47%)

73 (46%)

 

332 (46%)

13 (62%)

 

WHO performance, n (%)

  

0.001

  

0.51

  

0.72

 Able to carry out normal activity

426 (70%)

81 (60%)

 

394 (68%)

113 (70%)

 

493 (69%)

14 (67%)

 

 Restricted in physically strenuous activity

154 (25%)

37 (28%)

 

154 (27%)

37 (23%)

 

186 (26%)

5 (24%)

 

 Ambulatory

25 (4%)

16 (12%)

 

30 (5%)

11 (5%)

 

39 (5%)

2 (10%)

 

Comorbidity, n (%)

  

0.003

  

0.63

  

0.30

 None

180 (31%)

24 (20%)

 

164 (30%)

40 (27%)

 

200 (29%)

4 (24%)

 

 Mild

223 (39%)

41 (34%)

 

206 (37%)

58 (39%)

 

257 (38%)

7 (41%)

 

 Moderate

117 (20%)

38 (31%)

 

118 (21%)

37 (25%)

 

153 (22%)

2 (12%)

 

 Severe

57 (10%)

19 (16%)

 

62 (11%)

14 (9%)

 

72 (11%)

4 (24%)

 
 

Tumor biopsy

Yes

N = 142

Tumor biopsy

No

N = 597

P-value

Bloodd

Yes

N = 655

Bloodd

No

N = 84

P-value

Oral rinse

Yes

N = 650

Oral rinse

No

N = 89

P-value

Saliva

Yes

N = 436

Saliva

No

N = 303

P-value

Gender, n (%)

  

0.17

  

0.52

  

0.29

  

0.23

 Men

99 (70%)

450 (75%)

 

489 (75%)

60 (71%)

 

487 (75%)

62 (70%)

 

331 (76%)

218 (72%)

 

 Women

43 (30%)

147 (25%)

 

166 (25%)

24 (29%)

 

163 (25%)

27 (30%)

 

105 (24%)

85 (28%)

 

Age, mean ± SD years

62.5 ± 10.0

63.4 ± 9.8

0.29

63.4 ± 9.6

62.3 ± 10.5

0.36

63.3 ± 9.6

62.9 ± 11.1

0.73

64.0 ± 8.9

62.2 ± 10.8

0.022

Tumor location, n (%)

  

0.022

  

0.58

  

0.20

  

0.26

 Oral Cavity

41 (29%)

158 (26%)

 

173 (26%)

26 (31%)

 

168 (26%)

31 (35%)

 

105 (24%)

94 (31%)

 

 Oropharynx

56 (39%)

206 (34%)

 

232 (35%)

30 (36%)

 

229 (35%)

33 (37%)

 

166 (38%)

96 (32%)

 

 Hypopharynx

16 (11%)

36 (6%)

 

47 (7%)

5 (6%)

 

49 (8%)

3 (3%)

 

31 (7%)

21 (7%)

 

 Larynx

26 (18%)

179 (30%)

 

186 (28%)

19 (23%)

 

186 (29%)

19 (21%)

 

122 (28%)

83 (27%)

 

 Unknown primary

3 (2%)

18 (3%)

 

17 (3%)

4 (5%)

 

18 (3%)

3 (3%)

 

12 (3%)

9 (3%)

 

Clinical disease Stage, n (%)

  

0.020

  

0.74

  

0.08

  

0.35

 0/I

18 (13%)

145 (24%)

 

146 (22%)

17 (20%)

 

142 (22%)

21 (24%)

 

101 (23%)

62 (20%)

 

 II

28 (20%)

104 (17%)

 

118 (18%)

14 (17%)

 

121 (19%)

11 (12%)

 

70 (16%)

62 (20%)

 

 III

24 (17%)

103 (17%)

 

109 (17%)

18 (21%)

 

104 (16%)

23 (26%)

 

72 (17%)

55 (18%)

 

 IV

72 (51%)

245 (41%)

 

282 (43%)

35 (42%)

 

283 (44%)

34 (38%)

 

193 (44%)

124 (41%)

 

Treatment, n (%)b

  

0.39

  

0.043

  

0.15

  

0.86

 Single treatment

71 (50%)

322 (54%)

 

357 (55%)

36 (43%)

 

352 (54%)

41 (46%)

 

231 (53%)

162 (54%)

 

 Combination treatment

71 (50%)

274 (46%)

 

297 (45%)

48 (57%)

 

297 (46%)

48 (54%)

 

205 (47%)

140 (46%)

 

WHO performance, n (%)

  

0.028

  

0.13

  

0.97

  

0.046

 Able to carry out normal activity

86 (61%)

421 (71%)

 

456 (70%)

51 (61%)

 

445 (68%)

62 (70%)

 

309 (71%)

198 (65%)

 

 Restricted in physically strenuous activity

43 (30%)

148 (25%)

 

166 (25%)

25 (30%)

 

169 (26%)

22 (25%)

 

110 (25%)

81 (27%)

 

 Ambulatory

13 (9%)

28 (5%)

 

33 (5%)

8 (10%)

 

36 (6%)

5 (6%)

 

17 (4%)

24 (8%)

 

Comorbidity, n (%)

  

0.030

  

0.97

  

0.91

  

0.45

 None

30 (21%)

174 (31%)

 

180 (29%)

24 (31%)

 

178 (29%)

26 (32%)

 

129 (31%)

75 (27%)

 

 Mild

50 (36%)

214 (38%)

 

234 (38%)

30 (38%)

 

236 (38%)

28 (35%)

 

159 (38%)

105 (38%)

 

 Moderate

41 (29%)

114 (20%)

 

139 (22%)

16 (21%)

 

137 (22%)

18 (22%)

 

85 (20%)

70 (25%)

 

 Severe

19 (14%)

57 (10%)

 

68 (11%)

8 (10%)

 

67 (11%)

9 (11%)

 

46 (11%)

30 (11%)

 
  1. Patients with PROMs data, interview data or biobank samples may have missing data on components of the assessment. Groups were compared using chi square tests, unless otherwise specified. Significant p-values (p < 0.05) were printed in bold. Abbreviations: PROMs, patient-reported outcome measure, SD, standard deviation, WHO, World Health Organization
  2. aThe collected PROMs on education, family or personality were not taken into account, as patients were asked to complete these PROMs as part of the follow-up assessment in case data was missing
  3. bOne patient died before start of treatment and was therefore not included in the analysis on treatment
  4. cCompared using Fisher Exact Test
  5. dIncluding paxgene, serum, EDTA plasma, PBMC, PMN, EDTA platelet-free and/or platelets
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us